Aerovate Therapeutics Stock Analysis

AVTE Stock  USD 24.62  0.04  0.16%   
Aerovate Therapeutics is undervalued with Real Value of 27.87 and Target Price of 32.0. The main objective of Aerovate Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Aerovate Therapeutics is worth, separate from its market price. There are two main types of Aerovate Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Aerovate Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Aerovate Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aerovate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.

Aerovate Stock Analysis Notes

About 100.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 3.03. Aerovate Therapeutics had not issued any dividends in recent years. Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts. Aerovate Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 25 people. For more info on Aerovate Therapeutics please contact Timothy MBA at 617 443 2400 or go to https://aerovatetx.com.

Aerovate Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Aerovate Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Aerovate Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Aerovate Therapeutics had very high historical volatility over the last 90 days
Net Loss for the year was (75.52 M) with profit before overhead, payroll, taxes, and interest of 0.
Aerovate Therapeutics currently holds about 151.99 M in cash with (56.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22.
Aerovate Therapeutics has a frail financial position based on the latest SEC disclosures
Over 100.0% of the company shares are held by institutions such as insurance companies
Latest headline from MacroaxisInsider: Disposition of 10600 shares by Marinus Verwijs of Aerovate Therapeutics at 25.0 subject to Rule 16b-3

Aerovate Therapeutics Upcoming and Recent Events

3rd of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Aerovate Largest EPS Surprises

Earnings surprises can significantly impact Aerovate Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-03-30
2021-12-31-0.31-0.35-0.0412 
2022-11-14
2022-09-30-0.5-0.56-0.0612 
2023-05-15
2023-03-31-0.6-0.67-0.0711 
View All Earnings Estimates

Aerovate Therapeutics Environmental, Social, and Governance (ESG) Scores

Aerovate Therapeutics' ESG score is a quantitative measure that evaluates Aerovate Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Aerovate Therapeutics' operations that may have significant financial implications and affect Aerovate Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Aerovate Stock Institutional Investors

Shares
Eventide Asset Management, Llc2024-03-31
445.5 K
Octagon Capital Advisors Lp2024-03-31
403.7 K
Point72 Asset Management, L.p.2024-03-31
399.8 K
Ikarian Capital, Llc2024-03-31
368 K
Geode Capital Management, Llc2024-03-31
281.8 K
Ensign Peak Advisors Inc2024-03-31
262.3 K
State Street Corporation2024-03-31
230 K
Ghost Tree Capital, Llc2024-03-31
225 K
Woodline Partners Lp2024-03-31
200 K
Ra Capital Management, Llc2024-03-31
8.3 M
Sofinnova Ventures2024-03-31
3.8 M
Note, although Aerovate Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Aerovate Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 66 M.

Aerovate Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.59)(0.62)
Return On Capital Employed(0.74)(0.78)
Return On Assets(0.59)(0.62)
Return On Equity(0.69)(0.66)

Management Efficiency

Aerovate Therapeutics has return on total asset (ROA) of (0.4779) % which means that it has lost $0.4779 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8058) %, meaning that it created substantial loss on money invested by shareholders. Aerovate Therapeutics' management efficiency ratios could be used to measure how well Aerovate Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of June 18, 2024, Return On Tangible Assets is expected to decline to -0.62. In addition to that, Return On Capital Employed is expected to decline to -0.78. At present, Aerovate Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting.
Last ReportedProjected for Next Year
Book Value Per Share 4.16  2.51 
Tangible Book Value Per Share 4.16  2.51 
Enterprise Value Over EBITDA(7.05)(7.40)
Price Book Value Ratio 5.44  5.72 
Enterprise Value Multiple(7.05)(7.40)
Price Fair Value 5.44  5.72 
Enterprise Value573.1 M417.9 M
The analysis of Aerovate Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Aerovate Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Aerovate Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta
1.296
Return On Assets
(0.48)
Return On Equity
(0.81)

Technical Drivers

As of the 18th of June 2024, Aerovate Therapeutics shows the Downside Deviation of 5.68, risk adjusted performance of 0.0741, and Mean Deviation of 4.88. Aerovate Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Aerovate Therapeutics treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Aerovate Therapeutics is priced correctly, providing market reflects its regular price of 24.62 per share. Given that Aerovate Therapeutics has jensen alpha of 0.5237, we suggest you to validate Aerovate Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Aerovate Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Aerovate Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Aerovate Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Aerovate Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aerovate Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aerovate Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Aerovate Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Marinus Verwijs few days ago
Disposition of 10600 shares by Marinus Verwijs of Aerovate Therapeutics at 25.0 subject to Rule 16b-3
 
Gillies Hunter few days ago
Disposition of 6000 shares by Gillies Hunter of Aerovate Therapeutics at 24.5 subject to Rule 16b-3
 
Dorval Allison over a week ago
Acquisition by Dorval Allison of 12500 shares of Aerovate Therapeutics at 18.9 subject to Rule 16b-3
 
Marinus Verwijs over a month ago
Disposition of 1981 shares by Marinus Verwijs of Aerovate Therapeutics at 21.015 subject to Rule 16b-3
 
Noyes Timothy P over a month ago
Disposition of 1357 shares by Noyes Timothy P of Aerovate Therapeutics at 19.91 subject to Rule 16b-3
 
Noyes Timothy P over two months ago
Disposition of 5509 shares by Noyes Timothy P of Aerovate Therapeutics at 24.9428 subject to Rule 16b-3
 
Grayzel David S. over two months ago
Disposition of 11882 shares by Grayzel David S. of Aerovate Therapeutics at 28.15 subject to Rule 16b-3
 
Marinus Verwijs over three months ago
Disposition of 2764 shares by Marinus Verwijs of Aerovate Therapeutics at 26.4558 subject to Rule 16b-3
 
Benjamin Dake over three months ago
Disposition of 7581 shares by Benjamin Dake of Aerovate Therapeutics at 26.4825 subject to Rule 16b-3
 
George Eldridge over three months ago
Disposition of 114 shares by George Eldridge of Aerovate Therapeutics at 25.0 subject to Rule 16b-3
 
Gillies Hunter over three months ago
Disposition of 8975 shares by Gillies Hunter of Aerovate Therapeutics at 24.5 subject to Rule 16b-3
 
Dable Habib J over three months ago
Acquisition by Dable Habib J of 1531 shares of Aerovate Therapeutics at 22.49 subject to Rule 16b-3

Aerovate Therapeutics Predictive Daily Indicators

Aerovate Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Aerovate Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Aerovate Therapeutics Corporate Filings

8K
17th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
14th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10th of June 2024
Other Reports
ViewVerify
8K
7th of June 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
17th of May 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
8K
13th of May 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
3rd of May 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
F3
30th of April 2024
An amendment to the original Schedule 13D filing
ViewVerify

Aerovate Therapeutics Forecast Models

Aerovate Therapeutics' time-series forecasting models are one of many Aerovate Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Aerovate Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Aerovate Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Aerovate Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Aerovate shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Aerovate Therapeutics. By using and applying Aerovate Stock analysis, traders can create a robust methodology for identifying Aerovate entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Aerovate Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Aerovate analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Aerovate analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
32.0Strong Buy7Odds
Aerovate Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Aerovate analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Aerovate stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Aerovate Therapeutics, talking to its executives and customers, or listening to Aerovate conference calls.
Aerovate Analyst Advice Details

Aerovate Stock Analysis Indicators

Aerovate Therapeutics stock analysis indicators help investors evaluate how Aerovate Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Aerovate Therapeutics shares will generate the highest return on investment. By understating and applying Aerovate Therapeutics stock analysis, traders can identify Aerovate Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow22.4 M
Total Stockholder Equity109.5 M
Capital Lease Obligations675 K
Property Plant And Equipment Net902 K
Cash And Short Term Investments122.4 M
Net Invested Capital109.5 M
Cash23.5 M
50 Day M A21.2298
Net Interest Income5.2 M
Total Current Liabilities17.6 M
Investments20.7 M
Stock Based Compensation11.9 M
Common Stock Shares Outstanding26.3 M
Tax Provision56 K
Free Cash Flow-56.9 M
Operating Income-81.4 M
Other Current Assets1.8 M
Accounts Payable2.4 M
Net Debt-22.8 M
Depreciation96 K
Other Operating Expenses81.4 M
Non Current Assets Total3.2 M
Liabilities And Stockholders Equity127.4 M
Non Currrent Assets Other2.3 M

Complementary Tools for Aerovate Stock analysis

When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Global Correlations
Find global opportunities by holding instruments from different markets
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
FinTech Suite
Use AI to screen and filter profitable investment opportunities